Company: DVAX
Filing Date: 2025-04-03
Form Type: PREC14A
Source: 0000930413-25-001153
Chunk: 102

Company: DYNAVAX TECHNOLOGIES CORP
Filing Date: 2025-04-03
Form: PREC14A
Chunk 102
---
 During
this Community Involvement Day, all U.S. employees were encouraged to dedicate their day to volunteerism, and many employees volunteered
at local non-profits across the country. We also found several ways to support the Emeryville Unified School District with two scholarship
awards and guest speakers. We continue to provide all of our U.S. employees two paid days to volunteer in their local communities. Additionally,
from time to time, we make donations to support a variety of charitable organizations which we believe align with our core values.

Vaccine Access.We are
committed to developing and commercializing novel vaccines to help protect the world against infectious diseases, by
utilizing proven, innovative adjuvant technology. We are currently focused on our efforts to increase access and utilization
of our HEPLISAV-B vaccine through retail channels and integrated delivery networks, and we are advancing a pipeline of
differentiated product candidates that leverage our CpG 1018 adjuvant to develop improved vaccines in indications with unmet
medical needs. These programs include vaccine candidates under development for shingles and plague and additional vaccine
programs in preclinical development. We are currently conducting a randomized, active-controlled, dose escalation,
multicenter Phase 1/2 trial to evaluate the safety, tolerability, and immunogenicity of Z-1018 compared to Shingrix® in
441 healthy adults aged 50 to 69. We are also developing a plague (rF1V) vaccine candidate adjuvanted with CpG 1018® in
collaboration with, and fully funded by, the U.S. Department of Defense (“DoD”).

Additionally, we manufacture and have supplied in the past CpG 1018
adjuvant, the adjuvant used in HEPLISAV-B, through both commercial supply agreements and preclinical and clinical research collaborations
with third-party organizations. To support the fight against COVID-19, we collaborated with five other organizations on their development
of COVID-19 vaccines, by supplying them with CpG 1018 adjuvant under commercial supply agreements supported by two contract manufacturing
organizations, with whom we developed and implemented plans to help scale-up activities to support pandemic-level production of our CpG
1018 adjuvant as necessary to support these and any future collaborations. As of December 31, 2022, our delivery obligations under our
related supply agreements with all five organizations had been fully satisfied. We continue to work to identify other programs where CpG